Aromatase inhibitors (AIs) have been shown to be superior to Tamoxifen in the treatment of ER-positive breast cancer and the prevention of contralateral breast cancer in postmenopausal women with fewer side effects. The gene discussed is CYP19A1; the disease is breast carcinoma.